Metal Detoxification for Acute Myeloid Leukemia

This trial explores whether removing metals from the body can improve treatment outcomes for individuals with certain types of acute myeloid leukemia (AML), such as intermediate-risk or high-risk AML. The study incorporates metal detoxification using two chelating agents, Ca-EDTA and DMSA, into standard AML therapy to determine if it better controls the disease or enhances chemotherapy's effectiveness. Suitable candidates include those newly diagnosed with intermediate or high-risk AML, or secondary AML, who are not in complete remission after initial treatment. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

The trial protocol does not specify whether you need to stop taking your current medications. It's best to discuss your specific situation with the study team or your doctor.

Research is examining the safety of combining two treatments, Ca-EDTA (calcium disodium edetate) and DMSA (dimercaptosuccinic acid), for patients with acute myeloid leukemia (AML). Earlier studies have focused on understanding the side effects and determining the optimal dose for patients.

Ca-EDTA and DMSA typically remove metals from the body, a process known as chelation. Past research indicates that patients generally tolerate these treatments well. However, like any treatment, side effects can occur. Common side effects include stomach issues, such as nausea or an upset stomach, and mild skin reactions.

Researchers are excited about using Ca-EDTA and DMSA for treating acute myeloid leukemia (AML) because they introduce a novel approach: metal detoxification. Unlike standard treatments like chemotherapy, which target cancer cells directly, these agents work by removing toxic heavy metals from the body, potentially reducing the stress on healthy cells and improving overall outcomes. This method could offer a complementary angle to existing therapies, aiming to enhance their effectiveness and minimize side effects.

Studies suggest that certain treatments to remove metals from the body might improve outcomes for patients with acute myeloid leukemia (AML). In this trial, participants will receive a combination of Ca-EDTA and DMSA alongside standard AML therapy. These treatments aim to lower specific metal levels in the blood and bone marrow. Researchers believe that reducing these metal levels might enhance the body's response to chemotherapy. Although no direct evidence yet shows this treatment specifically benefits AML, these substances have successfully removed metals like lead from the body. This detoxification could potentially help control the disease or enhance the effectiveness of standard AML treatments.¹²³⁴⁵